Atea Pharmaceuticals, Inc. Common Stock
Symbol: AVIR (NASDAQ)
3.28
▲ (4.00%) 0.126
Company Description:
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Key Stats
- Today's Open: $3.14
- Today's High: $3.28
- Today's Low: $3.125
- Today's Volume: 20.15K
- Yesterday Close: $3.15
- Yesterday High: $3.23
- Yesterday Low: $3.095
- Yesterday Volume: 238.75K
- Last Min Volume: 2
- Last Min High: $3.28
- Last Min Low: $3.28
- Last Min VWAP: $3.28
Company Profile
- Name: Atea Pharmaceuticals, Inc. Common Stock
- Website: https://www.ateapharma.com
- Listed Date: 2020-10-30
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001593899
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $249.98M
- Round Lot: 100
- Outstanding Shares: 79.36M
- Asset Type: CS
RECENT FILINGS FOR AVIR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-07 | S-8 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 3 | View |
| 2025-06-20 | 8-K | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-04-29 | DEF 14A | View |
| 2025-04-23 | SCHEDULE 13G/A | View |
| 2025-04-17 | SCHEDULE 13D/A | View |
| 2025-04-17 | 8-K | View |
Latest News on AVIR